Spotlight: Dr. Ray is the current Director of our Future Labs bio-computing resource. Computation is rapidly becoming a n integral pa rt of life science research and development. Over the next decade, organizations that best integrate the use of bio-computation into their r esearch and development efforts will benefit greatly from leveraging this vastly powerful tool. Dr. Ray has consulted previously on drug discovery and medicinal chemistry (among others) for a variety of well known companies. Dr. Ray now brings his wealth of expertise and experience to our team providing a powerful resource toward assisting client’s with their therapeutics development challenges.

Interesting: In collaboration with Massachusetts General Hospital labs, Dr. Ray’s academic lab has pioneered discovery of molecules that have shown promise in treatment of Amyotrophic lateral sclerosis (ALS). These molecules have been licensed out to pharmaceutic al companies in the Boston area for pre-clinical development. In addition to his academic drug discovery interest, Dr. Ray is also the Co-founder Stemetix Pharmaceutical.

Background: Dr. Ray is also currently an Assistant Professor of Neurology at the Harvard University. His research is primarily focused on developing new computational and experimental technology to facilitate small molecule discovery in neurodegenerative diseases, such as Parkinson’s disease, Amyotrophic Lateral Sclerosis and Alzheimer’s disease. Prior to his appointment at Harvard, Dr. Ray studied at The Rockefeller University in New York where he received his doctorate in Protein Crystallography and Biophysics.

• Ph.D. – Protein Crystallography and Biophysics
  • Thesis work focused on the novel design of antibacterial agents to target MRSA

Though his primary focus is still neurodegenerative diseases, more recently Dr. Ray’s laboratory has been investigating the mechanistic details of protein kinases that are shared between neurological diseases and cancer.